|
09 May 2022 |
Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
|
|
09 May 2022 |
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
|
|
04 May 2022 |
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
|
|
04 May 2022 |
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
|
|
02 May 2022 |
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
|
|
01 May 2022 |
Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
|
|
01 May 2022 |
Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany
|
|
26 Apr 2022 |
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
|
|
26 Apr 2022 |
Update on Regulatory Submission for Aducanumab in the European Union
|
|
20 Apr 2022 |
VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
|
|
20 Apr 2022 |
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
|
|
19 Apr 2022 |
Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
|
|
14 Apr 2022 |
Ubix Therapeutics, SK Biopharmaceuticals enter into research collaboration agreement to develop novel therapeutics based on targeted protein degradation
|
|
13 Apr 2022 |
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
|
|
13 Apr 2022 |
Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
|
|
13 Apr 2022 |
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
|
|
13 Apr 2022 |
Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss
|
|
08 Apr 2022 |
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
|
|
08 Apr 2022 |
TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
|
|
08 Apr 2022 |
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
|
|
07 Apr 2022 |
HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
|
|
07 Apr 2022 |
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
|
|
07 Apr 2022 |
ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
|
|
07 Apr 2022 |
Almirall announces a new research collaboration with the University of Dundee to develop an innovative and differentiated treatment approach for dermatological diseases
|
|
07 Apr 2022 |
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
|
